*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Analysis of utilization of drugs for sickle cell disease in tertiary care hospitals

Author: MAGHIBEN M, DAMODARA VELAYUDHAM A, DR. T.UMAMAHESWARA RAO, DR M SMITHA
Abstract: Sickle cell disease (SCD) is an hereditary Issue initiated by An abandon in the gene to hemoglobin. Patients might bring you quit offering on that one faulty gene (sickle Mobile trait) or two faulty genes (sickle Mobile disease). and globally affects 1,00,000 people with 3,000 affected new born each year in US. The management of the indications of SCD comprises the usage of folate supplements, hydroxy urea, analgesics and antibiotics. Aim: The goal of the learning is to identify the medication utilization design in the organization of patient role with SCD in a tertiary care hospital. Methods: This is a prospective study carried out in general medicine and pediatrics ward of the hospital from November 2018 to April 2019. The information was collected from the case notes by the specially designed data collection form which comprised the demographic data, related co-morbid circumstances and list of prescribed drugs. Data was analyzed using descriptive analysis. Results: A total of 76 SCD patients with the mean age of 12.6 ± 11.3 years and 52.6 % of the affected roleis male. A entire of 515 drugs were arranged by an average of 6.7 drugs per preparation. Conclusion: High rate of folic acid is seen in the prescription with SCD patients followed by hydroxyurea and other hematinics. Our study recommends that WHO/ National Center for Biotechnology information reference guide to recover the patient excellence of life.
Keyword: Sickle Cell Disease, Drug utilization Pattern, Haematinics, Analgesics, Hydroxy urea
DOI: https://doi.org/10.31838/ijpr/2020.SP2.445
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free